Day: January 8, 2026

Midland, in Partnership with Rio Tinto Exploration Canada, Intersects New Lithium and Cesium Bearing Pegmatites During the 2025 Drilling Program on the Galinée Project

Written by Customer Service on January 8, 2026. Posted in Public Companies.

Figure 6Galinée 2024 Drilling ProgramFigure 2JB (North) Lithium OccurrencesFigure 1MD-RTEC Option for LithiumFigure 3Galinée ProjectFigure 7Iceberg Spodumene ShowingFigure 4Galinée 2024 Drilling ProgramFigure 5Galinée 2025 Drilling ProgramMONTREAL, Jan. 08, 2026 (GLOBE NEWSWIRE) — Midland Exploration Inc. (“Midland”) (TSX-V: MD), in partnership with Rio Tinto Exploration Canada Inc. (“RTEC”), is pleased to announce the results of the 2025 drilling campaign for lithium on the Galinée project. The Galinée project is located approximately 5 kilometres east of the Adina lithium deposit held by Winsome Resources (“Winsome”) and is subject to an option agreement signed with RTEC in June 2023 (see press release by Midland dated June 14, 2023) and amended in April 2024...

Profusa Adds Leading Greek Vascular Surgeon to Customer Base

Written by Customer Service on January 8, 2026. Posted in Public Companies.

Dr. Theodosios Bisdas is a renowned vascular surgeon and Head of Clinic of Vascular Surgery at the Athens Medical Center BERKELEY, Calif, Jan. 08, 2026 (GLOBE NEWSWIRE) — Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual’s biochemistry, announces a collaboration with Theodosios Bisdas, M.D., Ph.D., FACS, Head of Clinic of Vascular Surgery, Athens Medical Center, Greece, and previously Associate Professor for Vascular Surgery, Universitätsklinikum Münster, Germany. Dr. Bisdas has extensive experience in innovative endovascular techniques and is a member of the advisory boards of several medical technology companies for new vascular prostheses. Under the agreement, Dr. Bisdas...

Vera Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Written by Customer Service on January 8, 2026. Posted in Public Companies.

BRISBANE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) — Vera Therapeutics, Inc. (“Vera Therapeutics”), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced that the Company’s management team will present at the 44th Annual J.P. Morgan Healthcare Conference, which is taking place in San Francisco, CA from January 12-15, 2026. The management team will also participate in one-on-one investor meetings. Presentation Details:Date: Tuesday, January 13, 2026Time: 2:15 PM PSTWebcast: https://jpmorgan.metameetings.net/events/healthcare26/sessions/317196-vera-therapeutics-inc/webcast?gpu_only=true&kiosk=true A replay of the event will be available for 90 days and can be accessed by visiting the “Investor Calendar” section...

Plus Therapeutics Announces Read Out of Type B Meeting with the FDA with Goal of Accelerating Approval of REYOBIQ™ for Leptomeningeal Metastases

Written by Customer Service on January 8, 2026. Posted in Public Companies.

On track to define optimal dosing interval and advance manufacturing scale up of REYOBIQ for pivotal trial readiness in late 2026 HOUSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, announces the completion of a Type B meeting with the U.S. Food and Drug Administration (FDA) on next steps on REYOBIQ pivotal trial strategy for leptomeningeal metastases (LM). The meeting resulted in constructive discussion with the FDA regarding key elements of the potential pivotal study design for REYOBIQ in LM. Plus intends to incorporate the FDA’s feedback in the current dose optimization trial and seek alignment with the FDA on a revised protocol,...

ZenaTech Completes 20th Acquisition in Year One of Drone as a Service, Strengthening California Wildfire Management and Public Works Opportunities

Written by Customer Service on January 8, 2026. Posted in Mergers And Acquisitions.

VANCOUVER, British Columbia, Jan. 08, 2026 (GLOBE NEWSWIRE) — ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) (“ZenaTech”), a technology solution provider specializing in AI (Artificial Intelligence) drone, Drone as a Service (DaaS), enterprise SaaS, and Quantum Computing solutions, today announces it has completed its 20th acquisition. The most recent acquisition is L.D. King, Inc., a well-established civil engineering and land surveying firm based in the Los Angeles area, further strengthening its footprint for drone solutions in one of the most wildfire-sensitive and natural disaster-prone regions in the US. This acquisition caps a successful first year executing its Drone as a Service expansion strategy to enable drone accessibility at scale for the innovation of legacy, low tech or manual work. Since January...

Eupraxia Pharmaceuticals Reports Positive Tissue Health Data from its Ongoing RESOLVE Trial in Eosinophilic Esophagitis Demonstrating Near-Complete Improvement on Biopsy

Written by Customer Service on January 8, 2026. Posted in Public Companies.

At week 12, the highest dosed patients achieved the best tissue response seen in the trial to date, with a near complete improvement in tissue health1.At lower doses, patients maintained the improvements in tissue health1 reported at week 12 out until week 36.Clinical remission2 was achieved by 8 weeks and maintained through 52 weeks in the majority of patients for which more than 60% of their esophagus was treated.EP-104GI continues to be well tolerated by patients receiving the drug; over 200 patient-months of follow-up have been reported with no Serious Adverse Events (“SAEs”), and no cases of oral candidiasis.VICTORIA, British Columbia, Jan. 08, 2026 (GLOBE NEWSWIRE) — Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology...

Form 8.3 – [IDOX PLC – 07 01 2026] – (CGWL)

Written by Customer Service on January 8, 2026. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree IDOX PLC(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: IDOX PLC AS AN ASSOCIATE OF THE CANACCORD...

The Simply Good Foods Company Reports Fiscal First Quarter 2026 Financial Results and Reaffirms Fiscal Year 2026 Outlook

Written by Customer Service on January 8, 2026. Posted in Earnings Releases And Operating Results.

DENVER, Jan. 08, 2026 (GLOBE NEWSWIRE) — The Simply Good Foods Company (Nasdaq: SMPL) (“Simply Good Foods,” or the “Company”), a leader in the Nutritional Snacking Category, today reported financial results for the thirteen weeks ended November 29, 2025. First Quarter Summary:(1)Net sales of $340.2 million versus $341.3 million Net income of $25.3 million versus $38.1 million Earnings per diluted share (“EPS”) of $0.26 versus $0.38 Adjusted Diluted EPS(2) of $0.39 versus $0.49 Adjusted EBITDA(3) of $55.6 million versus $70.1 millionReaffirm Fiscal Year 2026(4) Outlook:Net sales expected to range between -2% and +2% year-over-year Gross margins expected to decline between 100 and 150 basis points year-over-year Adjusted EBITDA expected to range between -4% and +1% year-over-year“Our first quarter financial performance came...

Form 8.3 – [IDOX PLC – 07 01 2026] – (CGAML)

Written by Customer Service on January 8, 2026. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Full name of discloser: CANACCORD GENUITY ASSET MANAGEMENT LIMITED (for Discretionary clients)(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree IDOX PLC(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: IDOX PLC AS AN ASSOCIATE OF...

Invivyd Reports Preliminary Fourth Quarter 2025 Revenue and Recent Business Highlights

Written by Customer Service on January 8, 2026. Posted in Dividend Reports And Estimates.

Preliminary Q4 2025 PEMGARDA® (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth quarter-over-quarter Preliminary ending 2025 cash and cash equivalents of $226.7 million after raising over $200 million from financing transactions in 2H 2025 Announced initiation of DECLARATION Phase 3 pivotal clinical trial of vaccine-alternative antibody VYD2311 to prevent COVID, with top-line data expected mid-2026; Fast Track designation for VYD2311 granted by FDA in December 2025 Potential best-in-class RSV antibody VBY329 nominated for preclinical development Preclinical measles mAb candidate selection targeted for 1H 2026 for treatment and prevention of measles Further updates to be provided in conjunction with Form 10-K filing and upcoming ordinary quarterly reportingNEW HAVEN, Conn., Jan....

Day: January 8, 2026

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals